Chen Q,Lai Q,Jiang Y,Yao J,Chen Q,Zhang L,Wang C,Zhou Y,Deng M,Xu B M .2022 .Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway. , 25 : 101516-101516.
Yang Cui G,Y Cui G .2022 .Research progress of anlotinib in the treatment of advanced malignant tumors. Mod. Oncol. Med, 30(16) : 3032-3036.
Fang Y,Pan H,Shou J,Hong W,Guo Q,Yang X,Zhu D,Chen J,Lu L,Rao C,Lan F C .2021 .Anlotinib plus docetaxel versus docetaxel as second-line treatment for advanced non-small cell lung cancer (NSCLC): updated results from a phase I/II study. J. Clin. Oncol., 39(15 suppl)) : e21055-e21055.
Han Q,Hou H,Zhang X .2020 .Research progress on the anti-tumor treatment of domestically produced innovative drug Anlotini. Chin. J. New Drug. Clin. Med, 39(02) : 65-70.
Han Y,Wang J,Sun T,Ouyang Q,Li J,Yuan J,Xu B .2023 .Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer. Signal Transduct. Target. Ther., 8(1) : 429-429.
Hao H .2018 .Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase: Acatalytic receptor with many faces. Int. J. Mol. Sci, 19(11) : 3448-3448.
Isamu O,Hiroshi N,Shogo N,Seiji N,Shunichi S,Hidehito H,Koichi A,Yasuto Y,Haruyasu M,Yukio H,Shinji A,Tomohiro O,Atsushi H,Yuka F,Hiroaki O,Masahiko A,Nobuyuki Y,Yuichiro O,Kazuhiko N .2020 .Comparison of carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel monotherapy in elderly patients with advanced nonsquamous non-small cell lung cancer: Aphase 3 randomized clinical trial. JAMA Oncol., 6(5) : e196828.
Ji X,Jing X,Liu Y,Huang J,Yang S,Yun Y .2022 .Clinical application of anlotinib combined with docetaxel: Safe and effective treatment for lung carcinoma. Dis. Markers, 2483816 : 2483816.
Jin Y,Shimizu S,Li Y,Yao Y,Liu X,Si H,Sakurai H,Xiao W H .2023 .Proton therapy (PT) combined with concurrent chemotherapy for locally advanced nonsmall cell lung cancer with negative driver genes. Radiat. Oncol., 18(1) : 189-189.
Li Z,Quan C,Li W,Ji M .2023 .Synergistic effect of docetaxel combined with a novel multi-target inhibitor CUDC-101 on inhibiting human prostate cancer. Pathol. Res. Pract, 252 : 154938-154938.
Lin B,Song X,Yang D,Bai D,Yao Y,Lu N Y .2018 .Corrigendum to “Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1” [Gene 654 (. , 723 : 144119-86.
Liu M,Niu X,Liu H,Chen J .2023 .Germline EGFR mutations in lung cancer (Review). Oncol. Lett., 26(1) : 282-282.
Liu Z,Wang X,Li C,Zhao R .2023 .The function and mechanism of PSMD14 in promoting progression and resistance to anlotinib in osteosarcoma. Cancer Cell Int, 23(1) : 309-309.
Markers D .2023 .Retracted: Clinical application of anlotinib combined with docetaxel: Safe and effective treatment for lung carcinoma. Dis. Markers, 9826032 : 9826032.
Omer HA,Amin K,Grand K .2023 .(Noisy-le-. Cell. Mol. Biol, 69(11) : 81-91.
Parums D .2022 .Editorial: Recent approval of sotorasib as the first targeted therapy for KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). Med. Sci. Monit, 28 : e938746-e938746.
Pei S,Zhang X,Lu W .2023 .The efficacy of amlotinib hydrochloride combined with docetaxel in the treatment of advanced esophageal cancer and its impact on serum tumor markers and immune function. Chin. J. Clinicians, 51(04) : 443-446.
Taminya A .2023 .Long-term survival of patients with advanced non-small cell lung cancer treated using immune checkpoint inhibitors. Resp, 62(1) : 85-89.
Wang Q,Niu W,Pan H W .2021 .Targeted therapy with anlotinib for a H3K27M mutation diffuse middle glioma patient with PDGFR-α mutation: A case report. Acta Neurochir., 164(8) : 1-4.
Wang Y,Du J,Gong S J .2023 .Analysis of quality of life and prognostic factors in patients with stage I nonsmall cell lung cancer treated with stereotactic radiotherapy. J. Pract. Cancer., 38(07) : 1151-1147.
Wang Z,Wang C,Feng L C .2023 .The efficacy of immunotherapy combined with anlotinib in the treatment of refractory advanced non-small cell lung cancer. Chin. J. Clin. Ration. Drug Use, 16(35) : 74-77.
Wu C .2023 .The combined application of oral administration of anlotinib with docetaxel chemotherapy and intensity modulated radiotherapy in the treatment of early-stage small cell lung cancer after first-line treatment failure. Shandong Med, 63(06) : 51-54.
Yang S,Zhao Y .2023 .Evaluation of the efficacy of amlotinib hydrochloride in the treatment of advanced non-small cell lung cancer. Chin. J. Metall. Ind. Med, 40(04) : 449.
Yang W,Xuan B,Chen M,Li X,He J,Si H,Zhang Y,Front Y .2022 .Comparison of efficacy and safety between immunotherapy and docetaxel monotherapy in NSCLC patients#13. , 12 : 883514-883514.
Zhai X,Liu Y,Liang Z,Wang W,Qin T,Liu SV,Um S,Luo F,Liu J F .2022 .Classical ALK G1202R resistance mutation was identified in a lung adenocarcinoma patient with rare LOC388942-ALK fusion after sequential treatment with ALK-TKIs and anlotinib: A case report. Ann. Transl. Med, 10(21) : 1180-1180.
Yang Zhang L,X Zhang L .2023 .Comment on: quitting smoking at or around diagnosis improves the overall survival of lung cancer patients: Asystematic review and meta-analysis. J. Thorac Oncol., 18(2) : e17-e19.
Zheng W,Sun G,Li Z,Wu F,Sun G,Cao H,Zhou J,Ma Y,Front Y .2022 .The effect of anlotinib combined with anti-PD-1 in the treatment of gastric cancer#13. , 9 : 895982-895982.
Zhou Y,Li F,Zou B,Zhou X,Luo L,Dong S,He Z,Zhang Z,Liao L,Liu H,Cai C,Gu D,Duan X .2023 .β- Arrestin2 promotes docetaxel resistance of castrationresistant prostate cancer via promoting hnRNP A1- mediated PKM2 alternative splicing. Discov. Oncol., 14(1) : 215-215.
Zhu X,Yu Y,Lu S Y .2022 .Frontline treatment of advanced non-small cell lung cancer in the elderly. J. Pract. Oncol., 37(03) : 221-226.